The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). Patients (age 16-60 years) received induction therapy according to the AIDA protocol (all-trans retinoic acid, idarubicin) followed by one cycle of ICE (idarubicin, cytarabine, etoposide) and two cycles of HAM (cytarabine 3 g/m 2 q12h, days 1-3; mitoxantrone 10 mg/m 2 , days 2 and 3). From 1995 to 2003, 82 patients were enrolled. In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD). A total of 71 patients received at least one cycle of HAM. Relapsefree survival (RFS) and overall survival (OS) after 46 months were 83 and 82%, respectively. White blood cell count above 10.0 Â 10 9 /l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations. In conclusion, high-dose cytarabine in consolidation therapy for patients with newly diagnosed APL is an effective treatment approach. Leukemia (2005) 19, 978-983.
Introduction
The introduction of all-trans retinoic acid (ATRA) into the treatment of patients with acute promyelocytic leukemia (APL) has been a milestone in targeted therapy. [1] [2] [3] [4] [5] However, sustained remissions can only be achieved by the combination of ATRA with chemotherapy. [1] [2] [3] [4] [5] [6] [7] Retrospective analyses showed that in particular increasing doses of anthracyclines were associated with improved overall survival (OS). 8 There is some controversy as to the role of cytarabine and its dosage in the treatment of APL. While some treatment protocols completely omitted cytarabine, 4, 9 others even used high-dose or intermediate dose cytarabine in induction and consolidation therapy. 10, 11 In the pre-ATRA era, the good results with intensive double induction therapy including high-dose cytarabine suggested a potential role for high-dose cytarabine in APL (Lengfelder et al. Blood 1997; 90: 330; abstract) . 12 Additionally, the role of maintenance therapy with ATRA, low-dose chemotherapy or a combination of both has to be defined. 7, 10, 13 Two randomized trials showed a benefit for maintenance therapy with ATRA as single agent, 2, 7 and combination of low-dose chemotherapy with ATRA appears to further reduce relapse probability. 4, 7 However, maintenance therapy harbors the risk of side effects; 2, 4, 7, 10 the compliance of patients decreases markedly over time and close clinical monitoring is mandatory.
Studies in mice demonstrated that the APL-specific PML/RARa fusion protein and gain-of-function mutations in the tyrosin kinase FLT3 cooperate in inducing the APL phenotype, 14 whereas models with only one of these mutations did not result in overt leukemia. In line with this in vivo mouse model it was shown that activating FLT3 mutations, which occur in about 30-40% of APL patients, [15] [16] [17] confer a poor prognosis in this type of acute leukemia (Gallagher et al. Blood 2002; 100: 326; abstract).
The objectives of the present study were to evaluate the efficacy and toxicity of intensive consolidation therapy with high-dose cytarabine and to assess the clinical impact of known prognostic markers in this homogeneously treated population of APL patients.
Methods

Patient eligibility
Patients 16-60 years of age with M3 or M3v AML defined by the French-American-British (FAB) classification system 18 were eligible for entry into the trial. In all patients, the diagnosis of APL was confirmed by cytogenetic and molecular analysis. Initial bone marrow slides were reviewed centrally by one of us (UG). Written informed consent was obtained at study entry. The study was approved by the local ethics review committees of the participating institutions.
Cytogenetic and molecular genetic analyses
Chromosome banding analysis using standard methods were performed centrally in the Laboratory for Cytogenetic and Molecular Diagnostics of the AML Study Group (AMLSG). The description of the karyotype followed the recommendations of the International System for Human Cytogenetic Nomenclature. 19 All specimens were also analyzed by fluorescence in situ hybridization as previously described using a comprehensive set of DNA probes that allows to detect the most recurrent structural and numerical chromosomal abnormalities. 20, 21 Analysis of activating FLT3 mutations (FLT3 internal tandem duplication (ITD), FLT3 tyrosin kinase domain (TKD) mutations) were performed as previously described. 22 
Study design
All patients were assigned to two cycles of induction therapy with a cycle AIDA 23 
Supportive therapy
All patients were admitted to the hospital for induction and consolidation therapy. Treatment of coagulopathy during induction therapy was based on fresh frozen plasma and platelet support. At the first signs of suspected ATRA syndrome patients were given dexamethasone, and if symptoms aggravated ATRA was discontinued. Interventional administration of growth factors was allowed on the local investigator's decision.
Definitions and study endpoints
Definition of CR and partial remission (PR) followed published criteria. 24 Causes of therapeutic failure were subdivided into two categories: (i) refractory disease (RD), (ii) death less than 7 days after completion of the first induction therapy (early death, ED), or death during double induction therapy-induced bone marrow hypoplasia (hypoplastic death, HD). Relapse was defined as the occurrence of more than 10% blasts in two sequential bone marrow aspirates performed in a time interval of 2 weeks, or new extramedullary leukemia in patients with previously documented CR. The primary end points of the study were OS, relapse-free survival (RFS), cumulative incidence of relapse (CIR), and cumulative incidence of death (CID). OS end points, measured from study entry, were death (failure) and alive at last follow-up (censored). RFS end points, measured from data of first CR, were relapse (failure), death in CR (failure) and alive in CR at last follow-up (censored). Analyses of CIR and CID included only patients achieving CR with the time calculated from the date of CR until an event (relapse or death). ATRA syndrome was defined as the presence of five characteristic symptoms: fever, dyspnea, pleural and/or pericardial effusion, pulmonary infiltrates and unexplained weight gain. If three or four characteristic symptoms were present, ATRA-syndrome was suspected.
Statistical analysis
The median duration of follow-up was calculated according to the method of Korn. 25 The Kaplan-Meier method was used to estimate the distribution of OS and RFS as well as the probability of white blood cell (WBC) and platelet reconstitution times. 26 Confidence interval estimation was based on the cumulative hazard function using Greenwood's formula for standard error estimation. 27 CIR, CID, their standard errors (s.e.), and differences between groups were estimated using the method of Gray. 28 Associations between patient characteristics were assessed by the Mann-Whitney test for continuous variables and by Fisher's exact test for categorical variables. An effect was considered statistically significant if the P-value of its corresponding test statistic was 0.05 or less. Survival distributions were compared using the log-rank test. A Cox model was used to evaluate prognostic variables. 29 Missing data were estimated using a multiple-imputation technique using predictive mean matching with n ¼ 100 imputations. 30 A limited backwardselection procedure was used to exclude redundant or unnecessary variables. 30 The statistical analyses were performed with the statistical software package R, version 1.9.0 31 together with the Design software library. 30 
Results
Accrual of patients
Between January 1995 and April 2003, 88 consecutive patients with genetically proven APL from 19 institutions were registered. Six patients died due to cerebral hemorrhage before start of therapy without giving an informed consent. They are reported here for data comparability. 4, 32 Patient characteristics Table 1 shows the characteristics of the 82 eligible patients. In four of 82 cases, t(15;17) was only identified by molecular techniques; in all four cases there were no evaluable metaphases on conventional cytogenetics. Table 2 gives selected patient characteristics according to the FLT3 mutation status. There was a significant correlation between the presence of FLT3 ITD and WBC410 Â 10 9 /l (Po0.001) as well as with variant APL morphology (P ¼ 0.02); on the other hand, the frequency of additional chromosomal aberrations was lower in the FLT3 ITD group (P ¼ 0.01). Presenting features for the FLT3 TKD patients are also given in Table 2 , no statistical comparison was performed due to the low number of cases.
Induction therapy
Of the 82 patients eligible for this study first induction therapy was AIDA for 75 patients and ICE for the remaining seven patients. Of the 75 patients receiving AIDA as first induction therapy, 57 achieved CR, 11 PR, and seven patients died; five due to uncontrolled coagulopathy between days 3 and 7, two due to infection at days 12 and 25. Of the 68 patients receiving a second induction therapy with ICE, three patients died, two due to infection and one due to intracerebellar bleeding. Seven patients received ICE as first induction therapy since the diagnosis was initially not established on morphological criteria. All achieved CR after the first induction cycle; two received AIDA as second induction therapy, one received ATRA during consolidation therapy and four were treated with maintenance therapy (ATRA 45 mg/m 2 ) over a 6-month time period after completion of consolidation therapy. None of them relapsed. In total, 72 patients (88%, 95% confidence interval (CI): 79-93%) achieved CR after induction therapy, and 10 patients (12%, 95% CI: 7-21%) died due ED/HD. None of the patients had RD.
Patients dying during induction therapy had significantly (P ¼ 0.002) higher initial WBC counts and a higher likelihood of exhibiting þ 8 or abn(7q) as additional chromosomal aberrations (P ¼ 0.02). None of the other variables predicted for induction failure. Of the 75 patients receiving AIDA as first induction therapy, six and seven developed a suspected and a definite ATRA syndrome, respectively, that completely resolved in all of them. Two thromboembolic events were observed during ATRA therapy (cerebellar ischemia, deep venous thrombosis). Hematological and nonhematogical toxicity, supportive care and days in hospital during induction therapy are summarized in Table 3 .
Consolidation therapy
One patient did not receive consolidation therapy due to excessive toxicity (pleural effusion, cheilitis and keratoconjunctivitis) during induction therapy. This patient relapsed 8 months after completion of second induction therapy. After reinduction with AIDA and consolidation with HAM followed by myeloablative conditioning and autologous transplantation, this patient is in sustained CR. Of the remaining 71 patients, seven received only one cycle of HAM. In total, 64 patients completed the entire protocol with two cycles of HAM. There was one treatment-related death after the first cycle of HAM due to infection. Toxicity of the HAM cycles is summarized in Table 3 .
Survival analysis and prognostic factors
The estimated median follow-up time for survival was 46 months. Of the 82 patients, 15 have died resulting in an estimated survival probability after 46 months of 82% (95 CI: 74-91%). Of the 72 patients who entered CR, 10 relapsed, and one died during consolidation therapy resulting in a CIR and a CID after 46 months of 15% (s.e., 4.6%) and 1.4% (s.e., 1.4%), respectively. All relapsed patients received a reinduction therapy including ATRA or arsenic trioxide. Six patients achieved a second CR, one was refractory and three died during reinduction therapy. Four patients received an autologous transplantation in second CR. Known prognostic factors were evaluated in a multivariable Cox-regression model with limited backward selection. The model for OS revealed dichotomized WBC (cut point 10 Â 10 9 /l) 33 (HR 4.39, 95% CI: 1.54-12.52) and additional chromosomal aberrations (HR 3.54, 95% CI: 1.24-10.09) as prognostic factors, whereas no variable remained in the model for RFS. FLT3 ITD or TKD mutations did not show a statistically significant impact on OS or RFS. The negative prognostic impact of dichotomized WBC on OS is illustrated in Figure 1 .
Discussion
Our results show that intensive induction therapy followed by high-dose cytarabine in combination with mitoxantrone for consolidation therapy without additional maintenance therapy results in low CIR and high OS in newly diagnosed APL. However, our study is a singe-arm phase II-study lacking a control group. Therefore, it remains unclear which treatment element in our strategy accounts for the observed results: start of second treatment course at day 28, high-dose cytarabine and/or mitoxantrone in the third and fourth treatment course. Although we included only patients aged 16-60 years, the median age in our trial was comparable to or even higher than in other published trials including patients of all ages. 2, 3, 7 For induction therapy, we used the AIDA regimen 23 followed by a second intensive induction therapy resulting in a high CR rate of 88%, which is comparable to those achieved in other published trials in newly diagnosed APL. [1] [2] [3] 7, 10 Consistent with these trials, [1] [2] [3] 7, 10 the primary cause of induction failure was death due to coagulopathy. However, there were three toxic deaths in our study during second induction therapy with ICE, raising the question whether this approach was too dose-intense.
Comparable to the Medical Research Council (MRC) approach, 11 we used intensive consolidation therapy and omitted maintenance therapy. OS and RFS are comparable to those of the Spanish PETHEMA group that uses less intense consolidation in combination with a 3-year maintenance. 4, 33 In fact, several treatment approaches with different dose intensities lead to excellent OS-and RFS rates in newly diagnosed APL. However, it is unclear which approach is the best concerning the balance between treatment-related toxicity and clinical benefit. A comparison of the treatment strategies of the consecutive PETHEMA-trials suggests that, in particular, intermediate risk patients profit from intensification of the anthracycline-dosage during consolidation therapy. 32 Whether there is an additional role for high-dose cytarabine in consolidation therapy of high-risk patients remains open.
Looking for prognostic factors in our series, we applied the previously published cut point for WBC counts of the PETHEMA and GIMEMA group 33 and found significantly inferior OS in patients with initial WBC counts above 10 Â 10 9 /l. However, in contrast to the aforementioned study, this inferior prognosis for patients with initial high WBC counts was due to an increased ED/HD rate and not due to a higher CIR.
The incidence of mutant FLT3 was 42%, and FLT3 ITD was associated with high WBC at diagnosis, which is in accordance with previously published studies. [15] [16] [17] There was no impact of FLT3 ITD on OS and CIR. In contrast to reports using less intense treatment approaches showing inferior outcome for FLT3 ITDpositive APL patients (Gallagher et al. Blood 2002; 100: 326; abstract), 15 studies using a more intensive treatment approach 16, 17 like ours did not show a prognostic impact for these mutations.
There are conflicting data regarding the impact of additional chromosomal aberrations on the clinical outcome in APL patients. [34] [35] [36] [37] [38] In our series, þ 8 was the most frequent additional chromosomal aberration followed by abn(7q). Both additional aberrations were rarely associated with FLT3 ITD suggesting an alternative pathway of leukemogenesis 14 in these patients. The Cox-regression model for OS revealed additional chromosomal aberrations as an independent statistically significant negative prognostic marker. However, again this was due to an increased ED/HD rate in these patients and there was no statistically significant influence on CIR.
We conclude that our treatment strategy including high-dose cytarabine in consolidation therapy for patients with newly Table 3 Toxicity and supportive care requirements of induction and consolidation therapy High-dose cytarabine in acute promyelocytic leukemia RF Schlenk et al diagnosed APL is a feasible treatment approach. With respect to CIR, this strategy seems to overcome the negative prognostic impact of FLT3 ITD mutations, additional chromosomal aberrations, and high WBC counts.
